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INTRODUCTION
An overview is provided regarding some of the most com-
monly used measures to assess pain in adults. These measures 
are appropriate for both general and rheumatologic pain popula-
tions. Most measures are easy to use in clinical settings and all are 
validated for use in research. A number of well- known measures 
such as the Visual Analog Scale, Numeric Rating Scale, McGill 
Pain Questionnaire, and the Short Form 36 bodily pain subscale 
were described in a previous issue (1). Pain is complex, and thus 
it is important to conduct a comprehensive assessment. Here, 
we discuss several other measures that are helpful for assessing 
the severity, location, and quality of pain as well as pain- related 
interference in functioning. Further, knowing whether the pain is 
focal (ie, isolated to one area of the body) or more widespread can 
indicate the degree to which the pain is centralized in nature (2–5) 
and thus inform the treatment approach to the care of rheumatol-
ogy patients.
However, the assessment of pain (location, severity, and 
quality) and its impact on functioning cannot possibly tell the full 
story. Pain is a biopsychosocial phenomenon in which thoughts, 
emotions, and behavior contribute significantly to pain perception 
and pain outcomes. Although it is beyond the scope of this review 
to discuss all the possible contributing and potentially ameliorating 
factors and their measurement, a comprehensive assessment of 
pain for interdisciplinary treatment could also include an assess-
ment of underlying pain mechanisms, the perceived meaning of 
the pain, the level of pain acceptance, pain coping strategies, 
pain- related behavioral avoidance and/or fear (eg, kinesiophobia), 
and even resilience factors, including high levels of positive affect, 
strong social support, internal locus of control, and a sense of 
purpose in life.
Questionnaires presented here include the pain severity and 
pain interference subscales from the Brief Pain Inventory (BPI), the 
Defense and Veterans Pain Rating Scale (DVPRS), the Michigan 
Body Map (MBM), the painDETECT questionnaire (PD- Q), the 
Patient- Reported Outcomes Measurement Information System 
Pain Interference (PROMIS-PI) scales, and ambulatory assess-
ment of pain intensity, including the use of Ecological Momentary 
Assessment and daily pain diaries. The description of ambulatory 
assessments deviates from that of the other measures, given that 
this methodology diverges from the standard patient- reported 
outcome format. This form of pain measurement, however, is 
becoming the gold standard and, as such, is critical for clinicians 
and researchers to understand. Please see Tables 1 and 2 for 
an overview of psychometrics and practical applications, respec-
tively. The importance of considering other co- occurring symp-
toms such as sleep, mood, and fatigue will be described briefly, 
although their measurement will be covered in other sections of 
this special edition. More comprehensive measures of functional 




Purpose. The BPI is used to assess pain intensity and pain 
interference. It was originally developed for use in cancer popula-
tions (6) but has since been validated for use in many noncancer 
pain populations (7,8). There is both a long and short version of 
this measure, with the latter being used most often in clinical trials. 
The short version will be reviewed herein.
Content or domains. The BPI assesses the presence 
of pain, pain intensity (worst, least, average, and current), pain 
location (body map), and the impact of pain interference on 
general activity, mood, walking ability, normal work, relation-
ships with others, sleep, and life enjoyment. It also assists in 
documenting the types of pain medications being used and the 
amount of relief provided by those medications and other pain 
treatments.
Number of items. The BPI has a total of 15 items.
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Response options/scale. The BPI uses a mixture of 
response sets. Item 1 asks about the presence of pain (yes/no). 
Item 2 is a body map and asks the respondent to shade all areas of 
pain and to then place an x on the area that hurts the most. Items 3 
to 6 (pain intensity items: worst, least, average, and current) utilize 
an 11- point rating scale ranging from 0 (no pain) to 10 (pain as bad 
as you can imagine). Item 7 is an open- ended response field for 
listing pain medications. Item 8 (percentage of pain relief from med-
ications or pain treatments) uses a 0% (no relief) to 100% (complete 
relief) response scale. Item 9 has seven parts representing different 
aspects of pain interference (general activity, mood, walking ability, 
normal work, relationships with others, sleep, and life enjoyment). 
The response set for pain interference ranges between 0 (does not 
interfere) and 10 (completely interferes).
Recall period for items. The time frame for the BPI is typi-
cally the past week, but some versions also use the past 24 hours.
Cost to use. Licensing fees and $100 processing fees may 
be applied to use. Contact MD Anderson Cancer Center to inquire 
about fees for specific uses.
How to obtain. The BPI is copyrighted and validated intel-
lectual property. If interested, the contact information following con-
tact information may be used: Department of System Research, 
Attention: Assessment Tools, The University of Texas MD Ander-
son Cancer Center, 1515 Holcombe Boulevard, Unit 1450, Hou-
ston, TX 77030 (E- mail: symptomresearch@mdanderson.org).
Practical application
Method of administration. The BPI can be administered 
as a paper/pencil form, a computerized form, or an interview.
Scoring. Some of the items represent single- item values and 
do not require scoring (eg, pain relief). The pain severity score is 
obtained by calculating the mean of the four pain severity items. 
The pain interference score is obtained by calculating the mean of 
the seven pain interference items. The BPI is easily scored by hand.
Score interpretation. The pain severity score ranges 
between 0 and 10, with larger values representing greater pain 
severity. The pain interference score similarly has a range of 0 to 
10, with larger values representing greater pain interference.
Respondent time to complete. It takes approximately 
5 minutes to complete the BPI.
Administrative burden. Administrative burden is minimal 
unless an interview format is used. Typically, the form is simply 
handed to the participant to complete. Scoring involves calcu-
lating two means and can be accomplished in under 5 minutes.
Translations/adaptations. The BPI has been trans-
lated into over 50 languages. A complete listing of translations 
is available through the MD Anderson Cancer Center website 
(https://www.mdand erson.org/resea rch/depar tments-labs-insti 
tutes/ depar tments-divis ions/sympt om-resea rch/sympt om-asses 
sment-tools/ brief-pain-inven tory.html).
Psychometric information
Floor and ceiling effects. Floor and ceiling effects are 
not often reported for the BPI but are assumed to be adequate. 
 However, at least one study from the cardiac surgery literature 
suggested substantial floor effects both prior to and following 
 surgery, but minimal ceiling effects were noted (9).
Reliability. Internal consistency has been reported as being 
0.85 for the pain severity score and 0.88 for the pain interference 
score in noncancer pain populations (8). Test- retest reliability for 
daily administration up to 1 week ranges between 0.83 and 0.88 
for pain severity and between 0.83 and 0.93 for pain interference 
(10).
Validity. Thirty- six studies of the BPI in both cancer and 
noncancer populations across multiple languages support a two- 
factor structure for the BPI (ie, pain severity and pain interference) 
(11). Construct validity has been supported for the generic use of 
the BPI with chronic pain in over 72 studies (7), and it has been 
used to assess pain in over 400 studies with a wide variety of 
painful conditions. For example, in patients with arthritis, the BPI 
pain severity score correlated (r = 0.74) with the bodily pain scale 
of the Short Form 36 (a generic index of pain severity). Similarly, 
the BPI pain interference score correlated with the Chronic Pain 
Grade Disability Index (r = 0.81) and with the Health Assessment 
Questionnaire Disability Index (a disease- specific measure of func-
tional interference) (r = −0.69) (7).
Responsiveness. The BPI has demonstrated responsive-
ness to change in both pharmacological and nonpharmacological 
treatments (7,8,11).
Minimally important differences. In chronic pain 
states a two- to three- point change or 30% improvement in 
pain severity is considered meaningful. In a pharmacologi-
cal study of fibromyalgia, data were pooled across 12- week 
treatment periods from four randomized controlled trials 
and anchored against the patients’ Global Impressions of 
Improvement scale. For the BPI pain severity score, a 2.2- 
point change corresponded with a 34% reduction from base-
line scores (12). Few studies have estimated the minimally 
important difference (MID) for the BPI pain interference. One 
study of bone metastases that did, however, suggested an 
effect size of 0.05 SD (13).
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Generalizability. As stated, the BPI has been validated 
for use in multiple chronic pain conditions, both clinically and 
for research purposes. The constructs of pain severity and pain 
interference do not appear to be unique to any one form of pain, 
and therefore the items of this instrument appear to be relevant to 
chronic pain generally.
Use in clinical trials. Pain severity and pain interfer-
ence as constructs are recommended as core domains of 
assessment for clinical trials involving pain interventions. The 
BPI pain severity score and the BPI pain interference score 
are suggested indices for capturing these domains in clinical 
trials (14).
Critical appraisal of overall value to the  
rheumatology community
Strengths. The BPI was designed to be a monitoring tool 
for change in pain and its impact over time. Numerous studies 
support its valid use in this capacity.
Caveats and cautions. The BPI is considered an industry 
standard for the assessment of pain and its impact. It possesses 
strong psychometric properties for its pain severity score and its 
pain interference score. Far less is known about the other features 
of this instrument (eg, body map, medications, and pain relief), 
and these other features are rarely reported.
Clinical usability. The BPI is recommended for use in clini-
cal settings to monitor pain severity and pain interference.
Research usability. The BPI is also recommended for use 
in research because it is easily administered and possesses low 
patient burden.
DEFENSE AND VETERANS PAIN RATING SCALE
Description
Purpose. The DVPRS was developed to standardize assess-
ment of pain across Department of Defense and Veterans Health 
Administration health systems (15,16). Its first iteration incorpo-
rated the Faces Rating Scale–Revised, for which the International 
Association for the Study of Pain holds the copyright. To avoid 
copyright infringement, an alternative facial expressions scale was 
developed for a second version of the instrument (DVPRS version 
2.0).
Content or domains. The DVPRS consists of a pain inten-
sity item and four supplemental items. The supplemental items 
ask about how pain is interfering with usual activity, sleep, mood, 
and stress during the past 24 hours.
Number of items. The DVPRS consists of five items (a 
pain intensity item and four supplemental items).
Response options/scales. The pain intensity item com-
prises an 11- point numeric rating scale (NRS) (0- 10) that incorpo-
rates the following: 1) descriptions for each integer on the scale 
(eg, 0 = no pain, 1 = hardly notice pain, 5 = interrupts some activ-
ities, 10 = as bad as it could be/nothing else matters); 2) a traffic 
light coding system that groups pain intensity into mild (green: 
1- 4), moderate (yellow: 5- 6), and severe (red: 7- 10); and 3) a facial 
expressions scale. Four supplemental items are accompanied by 
an 11- point NRS in which 0 is anchored as “does not interfere” 
and 10 as “completely interferes.”
Recall period for items. The recall period for the pain 
intensity item of the DVPRS is the current time. The recall period 
for the pain interference items is the past 24 hours.
Cost to use. The DVPRS is free for clinicians and 
researchers to use with the proviso that the instrument remains 
unaltered.
How to obtain. The DVPRS can be downloaded from the 
Defense & Veterans Center for Integrative Pain Management website 
(https://www.dvcipm.org/clini cal-resou rces/defen se-veter ans- 
pain-rating-scale-dvprs/).
Practical application
Method of administration. A paper- based version of the 
DVPRS can be completed by the patient independently. Alter-
natively, responses can be obtained through an interview of the 
patient by the clinician.
Scoring. Separate scores are recorded for pain intensity 
and each of the supplemental items (interference with activity, 
sleep, mood, and stress over the past 24 hours). Each item has a 
possible range of 0 to 10.
Score interpretation. Higher scores on DVPRS items indi-
cate greater pain intensity or greater pain interference.
Respondent time to complete. The DVPRS takes 
approximately 3 minutes to complete (17).
Administrative burden. Given its ease of access, minimal 
time required for completion, and the small number of items, the 
DVPRS presents a low administrative burden.
Translations/adaptations. Spanish and Vietnamese 
versions of the scale are available (https://www.dvcipm.org/clini 
cal-resou rces/defen se-veter ans-pain-rating-scale-dvprs/).
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Psychometric information
A systematic literature search of manuscripts written in 
English through January 2017 restricted to adults with chronic 
(3 or more months) musculoskeletal pain was unable to iden-
tify studies of the reliability, validity, responsiveness to change 
or MID for the DVPRS (18). However, studies using the instru-
ment, including its postdevelopment preliminary evaluation, have 
examined its psychometric properties in less restrictive patient 
cohorts.
Floor and ceiling effects. Floor and ceiling effects of the 
DVPRS are yet to be investigated.
Reliability. Evaluation of the preliminary version of the 
DVPRS (version 1.0) using data from inpatients and outpatients 
with predominantly chronic noncancer pain or acute postop-
erative pain demonstrated a high level of internal consistency 
reliability (Cronbach’s α = 0.90 for the five items) (16). Subse-
quent examination of the DVPRS version 2.0 using data from 
active- duty military personnel and veterans also demonstrated 
acceptable internal consistency reliability (Cronbach’s α = 0.87) 
(15). Acceptable test- retest reliability for the pain intensity item 
(Pearson’s r = 0.64; P < 0.001) and the supplemental items 
(Pearson’s r of more than 0.70 for all items; P < 0.001) has also 
been reported (15).
Validity. Evaluation of the construct validity of the pre-
liminary version of the DVPRS (version 1.0) using principal 
component factor analysis found that one factor accounted 
for 72% of the variance in the measure (factor loadings for 
all five items of more than 0.82) (16). Subsequent examina-
tion of DPRS version 2.0 using data from active- duty military 
personnel and veterans supported a single- factor structure, 
explaining 66% of the variance in the measure (factor loadings 
for all five items of 0.53 or more) (15). However, in this study, 
a two- factor solution was supported when factor extraction 
was fixed, indicating the need for further evaluation and con-
firmatory factor analysis.
Preliminary evaluation of the content validity of the word 
descriptions integrated alongside the 11- point NRS demonstrated 
excellent agreement (intraclass correlation coefficient [ICC] = 0.94) 
(16).
Evidence supports the concurrent validity of the pain inter-
ference items of the DVPRS (19). The mean of the four DVPRS 
pain interference item scores has been shown to correlate 
with scores on the Pain Disability Questionnaire (PDQ) (Spear-
man’s ρ = 0.69; P < 0.001) and the Veterans RAND 36- item 
Health Survey bodily pain subscale (Spearman’s ρ = −0.65; 
P < 0.001), physical component subscale (Spearman’s 
ρ = −0.37; P < 0.001), and mental component subscale (Spear-
man’s ρ = −0.46; P < 0.001) (19). When examined  individually, 
the DVPRS pain interference onactivity item  correlated with 
the PDQ functional status component (Spearman’s ρ = 0.64; 
P < 0.001); DVPRS pain interference on mood and stress items 
correlated with scores on the PDQ psychosocial status compo-
nent and Beck Depression Inventory II scores; and the DVPRS 
pain interference on sleep item correlated with scores on the 
Insomnia Severity Index (Spearman’s ρ = 0.57; P < 0.001).
Responsiveness. The responsiveness to change of the 
DVPRS is yet to be investigated.
Minimally important differences. Minimal clinically 
important differences of the DVPRS items have not been empiri-
cally determined.
Generalizability. Given the context within which the 
DVPRS has been evaluated, generalizability is limited to active- 
duty military personnel and veterans.
Use in clinical trials. A search of ClinicalTrials.gov with the 
term “DVPRS” in January 2020 returned a list of 32 registered 
trials. As might be expected, the vast majority were conducted, 
or planned to be conducted, in military contexts or with veteran 
participants.
Critical appraisal of overall value to the  
rheumatology community
In the absence of comprehensive psychometric evaluation 
data specific to rheumatic and musculoskeletal disorders, the 
value of the DVPRS to the rheumatology community is arguably 
restricted to use in military contexts.
MICHIGAN BODY MAP
Description
Purpose. The MBM was developed to address the critical 
need for the availability of a body map that provides a quantifiable 
score and would be easy to use in clinical and research settings 
(20,21). The MBM has since been used in a wide range of studies 
in rheumatologic populations to assess the presence and location 
of chronic pain in 35 body areas (22–31).
Content or domains. The MBM consists of a graphic mani-
kin that depicts the front and back sides of an androgynous figure. 
Check boxes appear over 35 areas commonly reported as being 
painful (eg, lower back, neck, knees, wrists, hips, and head).
Number of items. The MBM consists of one activity: indi-
cating areas of the body affected by chronic pain.
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Response options/scale. Respondents are directed as 
follows: “On the image below, CHECK ALL areas of your body 
where you have felt persistent or recurrent pain present for the last 
3 months or longer (chronic pain).” Up to 35 body areas can be 
checked to indicate the locations of chronic pain.
Recall period for items. Respondents report persistent 
pain present over the last 3 months.
Cost to use. The MBM is free for both clinicians and 
researchers to use with the understanding that the measure 
remains unaltered and properly cited in publications.
How to obtain. The MBM and links to original publications 
and scoring syntax can be obtained at https://medic ine.umich.edu/
dept/pain-resea rch/clini cal-resea rch/michi gan-body-map-mbm.
Practical application
Method of administration. The MBM is a self- 
report measure and can be administered using either a pen and 
paper form or an electronic version of the MBM (eMBM) (32). The 
respondent is asked to check every box that indicates an area 
where they have experienced chronic pain.
Scoring. Although the MBM is predominantly used to indi-
cated areas of chronic pain, a score can be derived by totaling the 
number of body areas impacted.
Score interpretation. In addition to providing information 
about the location of a patient’s chronic pain, the MBM is thought 
to be most useful for showing the degree to which a patient’s pain 
is widespread. The endorsement of numerous body areas and/
or the endorsement of locations across several body zones (eg, 
right upper quadrant, right lower quadrant, left upper quadrant, 
left lower quadrant, and head) suggest the presence of a more 
centralized pain state (ie, fibromyalgia) (33).
Respondent time to complete. The MBM takes less 
than 1 minute to complete (21).
Administrative burden. There is little burden associated with 
this measure. It is readily available in paper and electronic forms, is 
easy to understand, takes only a few minutes for respondents to com-
plete, and requires no specific training to score and interpret.
Translations/adaptations. The MBM has been trans-
lated into German, Chinese, Portuguese, and Yiddish, although 
none of these translations have undergone formal validation.
Psychometric information
Floor and ceiling effects. Floor and ceiling effects have 
yet to be investigated in the MBM or eMBM.
Reliability. In a study evaluating test- retest reliability, 
patients completed the MBM and then returned to the clinic for 
a retest 1 to 2 weeks later. The Wilcoxon signed- rank test and 
dependent samples t-test were used to assess the test- retest 
reliability of the MBM. Half of respondents had zero or one dis-
crepant body areas between the two administrations. Percentage 
agreement for each body part from first administration to second 
ranged from 85% to 100%. The correlation between total number 
of body areas checked at each administration was positive and 
statistically significant. The time to complete the MBM was similar 
between the initial and follow- up administrations 1 to 2 weeks 
later (21).
Validity. In a study of convergent and discriminant valid-
ity, patients with pain (n = 237) completed the MBM and the 
following commonly used measures of pain outcomes: the BPI 
(pain severity and pain interference subscales), the PD- Q, the 
Oswestry Disability Index, the Catastrophizing Subscale from 
the Coping Strategies Questionnaire, and the Hospital Anx-
iety and Depression Scale (HADS). The correlations between 
the MBM and each of the pain- related constructs were posi-
tive. Correlations of this magnitude suggest that less than 17% 
of the variance in each of these other scales overlaps with the 
MBM measure. Thus, in assessing the degree to which pain is 
pain widespread, the MBM is assessing a somewhat unique 
construct that has positive associations with other metrics of 
pain (21).
Responsiveness. The MBM is typically used as a method 
of assessing pain location and is commonly used as a predic-
tor variable when it is thought that the number of painful sites 
endorsed could be informative.
Minimally important differences. Not applicable.
Generalizability. The MBM has been translated into sev-
eral languages and is used in a broad array of settings, including 
in different countries, for noninflammatory and inflammatory pain 
conditions, and in surgical settings. Such wide use supports the 
generalizability of the MBM.
Use in clinical trials. The MBM has been or is being used 
as an assessment measure in a number of prospective cohort 
studies and clinical trials for patients with both acute and chronic 
pain.
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Critical appraisal of overall value to the  
rheumatology community
Strengths. The MBM was designed to address a need in 
pain location assessment—to provide a validated body map that 
yields a quantifiable measure of the spread of pain across the 
body.
Caveats and cautions. The MBM is still relatively new, 
and more validation work in diverse patient populations is 
needed.
Clinical usability. The MBM is recommended for use in 
clinical settings to assess and monitor the location of pain and 
changes in location over time.
Research usability. The MBM is recommended for use 
in research because it provides a score from 0 to 35 that can 
easily be used to assess whether a patient’s pain is focal or 
widespread. Furthermore, the MBM can also be used for the 
assessment of the fibromyalgia survey criteria (33,34). Of the 
35 body areas denoted in the MBM, 19 correspond with those 
in the Widespread Pain Index, which is one of two compo-
nents of the fibromyalgia survey criteria (34). This latter fea-
ture has made the body map a particularly helpful tool for the 
assessment of fibromyalgia- like or centralized pain in many 
populations (22,24–26,30,31,35,36). The presence of pain that 




Purpose. The PD- Q was developed as a screening tool to 
determine the likelihood of the presence of pain of neuropathic 
origin (37).
Content or domains. The PD- Q includes three questions 
about pain intensity (current pain, the strongest pain during the 
past 4 weeks, and how strong the pain was during the past 4 
weeks on average). A body manikin is used to collect information 
about the main area of pain. Seven items inquire about the pres-
ence and quality of neuropathic pain symptoms (eg, burning sen-
sation or tingling/prickling sensations). One item asks about the 
course of pain over time, and one item asks whether pain radiates 
to other regions of the body.
Number of items. The PD- Q includes 13 items. Responses 
to nine of these items are summed to derive a total PD- Q score.
Response options/scales. The three questions about 
pain intensity are accompanied by 11- point NRS (0- 10). 
Respondents are asked to mark their main area of pain on a 
body manikin. The items that ask about the presence and quality 
of neuropathic pain symptoms (eg, burning sensation) have Lik-
ert response options ranging from 0 (never) to 5 (very strongly). 
The item that asks about the course of pain over time has four 
response options, each accompanied by a representative illus-
tration (persistent pain with slight fluctuations, persistent pain 
with pain attacks, pain attacks without pain between them, 
and pain attacks with pain between them). The item that asks 
whether pain radiates to other regions of the body also asks 
respondents to mark the direction in which the pain radiates on 
the body manikin.
Recall period for items. The recall period for the PD- Q is 
the current time or over the last 4 weeks (38).
Cost to use. The PD- Q is free for clinicians and research-
ers to use with the understanding that no alterations are made to 
the measure.
How to obtain. An English language version of the PD-Q 
can be retrieved from the original publication (37).
Practical application
Method of administration. The PD- Q can be completed 
by the patient independently using paper and pencil.
Scoring. Responses to nine of the 13 items are used to 
create a summary score, with a possible range of −1 to 38. 
Summed items include the seven items that ask about the pres-
ence and quality of neuropathic pain symptoms (possible range 
of 0 [never] to 5 [very strongly] for each item), responses to the 
item about the course of pain (0 = persistent pain with slight 
fluctuations, −1 = persistent pain with pain attacks, 1 = pain 
attacks without pain between them, and 1 = pain attacks with 
pain between them), and the item that asks about radiating pain 
(2 if yes, 0 if no).
Score interpretation. The sum of the nine scored items 
of the PD- Q are used to determine the likelihood of the presence 
of neuropathic pain. Scores of 12 or less indicate that a neuro-
pathic component of pain is unlikely, scores from 13 to 18 are 
ambiguous, and scores of 19 or more indicate that a neuropathic 
component of pain is likely.
Respondent time to complete. The PD- Q takes approx-
imately 5 minutes to complete (38).
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Administrative burden. Given its ease of access and 
completion and the relatively small number of items, the PD- Q 
presents a low administrative burden.
Translations/adaptations. The PD- Q was originally 
developed in German. It has been extensively translated and 
cross- culturally adapted and is available in more than 23 lan-
guages (39).
Psychometric information
Floor and ceiling effects. In a study of inflammatory arth-
ritides (rheumatoid arthritis, psoriatic arthritis, and spondyloarthri-
tis), no ceiling effect was observed for the PD- Q (40).
Reliability. A systematic critical appraisal of the measure-
ment properties of the PD- Q determined that there was evidence 
for satisfactory internal consistency reliability, although the level of 
evidence was judged as being very low (41). Internal consistency 
reliability for chronic low back pain specifically has been estimated 
as Cronbach’s α = 0.76 (42).
Test- retest reliability of the English version of the PD- Q using 
pre- and postconsultation data indicated almost perfect agree-
ment (ICC = 0.91, 95% confidence interval [CI] 0.88- 0.94) (39). In 
the same study, there was substantial agreement between pre-
consultation scores and scores collected 1 week later (ICC = 0.79, 
95% CI 0.70- 0.88). Classification by neuropathic pain status per-
formed similarly well when comparing pre- and postconsultation 
scores (weighted κ = 0.77, 95% CI 0.68- 0.86), and when com-
paring preconsultation scores and scores collected 1 week later 
(weighted κ = 0.69, 95% CI 0.55- 0.83) (39).
In a study of inflammatory arthritides (rheumatoid arthritis, 
psoriatic arthritis, and spondyloarthritis), Rasch analysis indicated 
acceptable psychometric properties. Principal component analy-
sis supported a one- item structure, test- retest reliability demon-
strated strong agreement (ICC = 0.94, 95% CI 0.84- 0.98), and 
classification consistency was strong (80%) (40). Rasch analysis 
has also supported the acceptability of the psychometric proper-
ties of the instrument when applied to a sample of patients with 
osteoarthritis (43).
Validity. A systematic critical evaluation of the measure-
ment properties of the PD- Q determined that the instrument has 
satisfactory criterion validity but unsatisfactory content validity, 
although the level of evidence for both was very low (41).
The original German version of the PD- Q had a sensitivity of 
85% and specificity of 80% in identifying neuropathic pain among 
adults with chronic low back pain (37). Sensitivity and specificity 
were less satisfactory for a sample of patients with neck/upper- 
limb conditions who completed an English version of the instru-
ment (64% and 62%, respectively) (44).
Construct validity of a form of the PD- Q modified for use with 
people with knee osteoarthritis has been reported as satisfactory, 
although the evidence level was judged as low (41,45).
Responsiveness. The responsiveness to change of the 
PD- Q is yet to be investigated.
Minimally important differences. Not applicable.
Generalizability. The PD- Q has been translated, cross- 
culturally adapted, and tested in different countries and languages 
and for noninflammatory and inflammatory pain conditions. This 
breadth of research supports the generalizability of the instrument.
Use in clinical trials. The PD- Q has been or is being used 
as an outcome measure in clinical trials of pharmacological and 
nonpharmacological interventions for neuropathic pain.
Critical appraisal of overall value to the  
rheumatology community
The psychometric properties of the PD- Q indicate that it may 
be useful for detecting pain of neuropathic origin in patients with 
chronic low back pain, inflammatory arthritides, or osteoarthritis but 
less useful in patients with neck or upper- limb conditions.
PROMIS PAIN INTERFERENCE SCALES
Description
Purpose. The National Institutes of Health Common Fund 
initiative known as the PROMIS (46,47) developed a collection 
of psychometrically rigorous outcomes measures across multiple 
domains. One of these domains is pain interference, a construct 
that broadly assesses the consequences of pain on physi-
cal, mental, and social activities.
Content. The PROMIS-PI item banks assess the construct 
of pain interference, which is the extent to which pain impacts 
engagement in social, cognitive, emotional, physical, and recrea-
tional activities. It also includes elements of sleep and life enjoyment.
Number of items. The entire PROMIS- PI item bank is 
defined by 41 items; however, there are several short forms with 
strong relationships to the entire item bank that contain four, six, 
and eight items. The PROMIS- PI can also be assessed using 
computer adaptive testing (CAT).
Response options/scale. The PROMIS- PI item bank 
uses three different response sets. Each type of interference is 
evaluated on a scale of not at all, a little bit, somewhat, quite a 
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bit, and very much (response set A); never, rarely, sometimes, 
often, and always (response set B); or never, once a week or 
less, once every few days, once a day, and every few hours 
(response set C).
Recall period for items. All items use a 7- day recall.
Cost to use. The PROMIS- PI is free for individual and aca-
demic use. There can be fees associated with study- related ser-
vices and administration for longitudinal uses.
How to obtain. HealthMeasures distributes many of the 
PROMIS measures (http://www.healt hmeas ures.net/index.
php).
Practical application
Method of administration. Administration of short- form 
versions can be by paper and pencil or computer/tablet/smart-
phone. Administration of the PROMIS- PI CAT requires a com-
puter/tablet/smartphone.
Scoring. PROMIS instruments use item- level calibrations. 
Although there are tables that can convert raw scores into stand-
ardized T scores, you must have complete data for this method to 
be valid (ie, no missing data). The most accurate method of scor-
ing is to use a data collection tool that automatically calculates 
scores (eg, Research Electronic Data Capture autoscore) or the 
Health Measures scoring service (https://www.asses sment center.
net/ac_scori ngser vice).
Score interpretation. Raw scores are converted to popu-
lation T scores with a mean of 50 and an SD of 10. For example, 
a score of 60 is 1 SD greater than the population mean. Higher 
scores are indicative of more of the construct being measured; 
thus, in this example, 1 SD more pain interference than the pop-
ulation mean. Cut points for PROMIS- PI T scores include the 
following: 0 to 54 for normal, 55 to 59 for mild, 60 to 79 for mod-
erate, and 70 to 80 or more for severe. Normal and mild pain 
interference accounts for approximately 80% of the general popu-
lation, whereas moderate to severe pain interference accounts for 
the remaining 20% (48).
Respondent time to complete. It takes between 45 sec-
onds and 1.6 minutes to complete this assessment, depending 
on the version being used.
Administrative burden. Administrative burden is minimal 
because the PROMIS- PI can be administered electronically or via 
paper and pencil. Scoring can be done by hand, by computer, or 
by a service.
Translations/adaptations. The PROMIS- PI has been 
translated into many different languages. A complete list is availa-
ble on the HealthMeasures website (http://www.healt hmeas ures.
net/explo re-measu rement-syste ms/promi s/intro-to-promi s/avail 
able-trans lations).
Psychometric information
The PROMIS measures were developed using item 
response theory (IRT) methodology as opposed to classical 
test construction theory. An item pool for pain interference 
was developed to represent the construct. Different assess-
ment forms using different combinations of items (eg, four, 
six, and eight or CAT) can be used to index the overall pool of 
items. The PROMIS- PI item bank has an overall Cronbach’s 
α of 0.99, is factor analytically unidimensional, can be reli-
ably administered to reflect the construct with short forms 
of minimal burden (eg, four, six, and eight) or with CAT, and 
experiences minimal differential item functioning with varying 
respondent demographics (49).
Floor and ceiling effects. None. Endorsement of “no pain 
interference” is adequately scaled along with high ranges of pain 
interference without reaching scaling obstacles.
Reliability. The PROMIS- PI item bank retains highest 
information between a T score of 40 (ie, 1 SD below the pop-
ulation mean) to 80.4 (ie, 3 SDs above the population mean). 
The majority of the validation sample responses fell within this 
range, which is equivalent to reliability of 0.96 to 0.99 across 
this range. In the validation sample, no individual scores fell 
below a T score of 40, and only five individuals (ie, 1%) scored 
above 80. The degree of information/precision increased with 
greater numbers of items (ie, four, six, and eight) but all had 
reliability above 0.95 for scores ranging between 40 and 80 
(49). In a rheumatologic sample, test- retest reliability of the 
CAT (ie, smallest number of items [eg, three]) was 0.88 for a 
2- day interval (50).
Validity. Construct validity of the PROMIS- PI is supported 
by strong correlations with legacy measures of the same construct 
(ρ = 0.90), similar pain constructs (ρ = 0.84), and lesser associ-
ations with differing constructs such as mental health (r = 0.33), 
depression (r = 0.35), and anxiety (r = 0.35) (49). Similar support 
for convergent and divergent validity was found for rheumatic 
conditions (50).
Responsiveness. The PROMIS- PI showed a dose- 
response relationship with rheumatic disease severity, with 
responsiveness being identified even at the low end of symptoms 
and in individuals with minimal disease activity (50,51).
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Minimally important differences. In a study of low back 
pain, the MID for PROMIS- PI was estimated to be between 3.5 
and 5.5 points (52).
Use in clinical trials. Pain Interference is increasingly rec-
ognized as a core outcome in clinical trials for chronic pain (14).
Critical appraisal of overall value to the  
rheumatology community
Strengths. The IRT methodology used to develop and val-
idate the PROMIS- PI makes it psychometrically superior to most 
legacy measures of the same construct, both in terms of precision 
and minimal patient burden. Legacy measures are static and often 
require all items to be completed to be valid even if the additional 
items add no new information—PROMIS measures do not share 
this weakness (49).
Caveats and cautions. The psychometric evaluation of an 
IRT- based instrument is different from one developed using classi-
cal test theory. Many potential users or funders do not understand 
how different versions of the same item bank using a short form or 
CAT can be equally reliable and valid indices of the same construct.
Clinical usability. When multiple domains of assessment 
are needed, the CAT version of the PROMIS item banks can be 
the most efficient. Domains can be compared with each other and 
interpreted easily because they all use the same T score metric.
Research usability. The static short forms are more com-
monly used in the research settings in which access to CAT scor-
ing algorithms may be more limited.
AMBULATORY ASSESSMENT OF PAIN INTESITY
Description
Other measures covered in this article rely on respondent’s 
retrospective recollection of their pain experience over a specified 
time frame, such as pain in the past week or month. In contrast, 
ambulatory assessment methods of measuring pain involve repeat-
edly assessing pain experiences in a person’s natural environment 
in real time (ie, report on current experience) or for proximal recall 
time frames (eg, since the last pain assessment or in the last day). 
Here the term “ambulatory assessment” refers to self- report meth-
odologies otherwise commonly known as “ecological momentary 
assessment,” “experience sampling,” or “daily diaries.”
Purpose. Pain intensity is a highly variable symptom even 
over short time frames, and ambulatory assessment of pain is 
uniquely able to assess pain with high precision and reliability. Use 
of repeated ambulatory assessments of pain provides a number 
of significant advantages compared with one- time recall surveys. 
Ambulatory assessment of pain allows for the examination of the 
dynamics of pain fluctuations in daily life (53). Unlike pain rat-
ings collected in the clinic or laboratory, ambulatory assessment 
approaches have good ecological validity because they reflect the 
experience of pain in a person’s natural environment (54,55). Fur-
thermore, this approach does not rely on memory of past pain 
experiences and is therefore less subject to recall biases, including 
peak and recency effects on pain ratings (56–58).
Number of items/assessments. There is some incon-
sistency in terms of precisely how many ambulatory assessments 
are needed for a reliable assay of pain in clinical trial research 
(59–61), with one study finding that a single 24- hour rating of pain 
had high validity and reliability for detecting treatment effects (62) 
and others showing that a single momentary assessment is not 
adequately reliable as a trial outcome (61) and that a composite of 
at least 5 days of 24- hour pain ratings is necessary to reach ade-
quate measurement reliability (63). However, ambulatory assess-
ments are regarded as the most reliable means of assessing pain 
intensity (64), and this approach is consistent with the most recent 
US Food and Drug Administration (FDA) guidelines for the devel-
opment of analgesic treatments, which require that clinical trial 
end points assess recent pain experience, with recall time frames 
of no longer than the past 24 hours (65).
Practical application
Although respondent burden is often a concern among 
those considering using ambulatory assessment of pain intensity, 
available data suggest that these methods are feasible for use in 
chronic pain populations. Although there are unusual examples of 
studies with data collection protocol compliance of less than 50% 
(66,67), average completion rates typically fall in the range of 85% 
to 90% (68,69), and completion rates are high even in populations 
in which chronic pain is secondary to a primary disabling condition 
(70–72). Another common concern in pain assessment is about 
reactivity to the ambulatory assessment methods, that is, con-
cern that repeatedly asking for pain ratings in real- life settings will 
alter the respondent’s perceptions and ratings of pain. However, 
a set of studies in diverse populations has found no evidence for 
reactivity to repeated ambulatory assessment of pain (64,72–75).
Despite the benefits of ambulatory assessment of pain 
intensity, one major limitation is that methods are currently not 
standardized, and there is tremendous heterogeneity in ambu-
latory methods used across published studies (68).There is var-
iability across studies in terms of the wording of the pain item 
stem, the response scale, the data input modality, the duration 
of assessment, the frequency of assessment, and the assess-
ment schedule. There is no standard wording for pain items in 
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 ambulatory assessments, and researchers have either replicated 
wording they find in published research, created a new item stem, 
or adapted wording from existing recall measures (72,76). In terms 
of response scale, prior studies have most commonly used a 
numerical rating scale, although visual analog scales and verbal 
ratings scales have also been popular (77). Of these three options, 
data on patient preference, ease of administration, responsive-
ness to change, and overall psychometric quality suggest that the 
NRS is the best overall for assessing pain intensity (69,78–84). 
The range of response scales also varies widely across studies, 
although the most common practice is to use a 0 to 10 NRS, 
which is consistent with common procedures in clinical care and 
with the current pain intensity outcome measurement recommen-
dations from the Initiative on Methods, Measurement, and Pain 
Assessment in Clinical Trials (14).
Ambulatory pain data has been collected via paper logs/
diaries (85–87), palmtop computers (88), wearable devices (eg, 
watches) (70,89–91), and smartphone applications (92,93). With 
growing ubiquity of wearable technology and smartphones, use 
of these devices to collect ambulatory pain data in research has 
grown tremendously, particularly since 2010 (68). Although pain 
studies have collected data for various lengths of time, ranging 
from 1 day to more than 1 year, the most common data collection 
periods are 1 week or 2 continuous weeks of assessment (68). 
Similarly, frequency or intensity of data collection is also highly var-
iable, although on average studies assess pain 5 times/day (68). 
There is also variability in the sampling schedule used across pain 
studies, although most studies use a time- based fixed or random 
sampling schedule (68). It is likely that some flexibility in ambula-
tory assessment methods is needed to address different types of 
research questions and to meet different clinical and study needs. 
However, there is a clear need for more rigorous psychometric 
evaluation and the development of clear standards for ambulatory 
assessment methods.
Critical appraisal of overall value to the  
rheumatology community
Strengths. Ambulatory assessment of pain intensity 
is uniquely capable of capturing the daily fluctuations in pain 
severity common in people with rheumatologic conditions. 
Because pain ratings are given in real time or require recall of 
proximal time frames, ambulatory assessment does not suffer 
from recall bias and provides an optimally reliable assay of pain 
when collected over a series of days. Because pain intensity is 
collected in the wild as respondents go about their daily lives, 
it is considered to have better ecological validity than pain rat-
ings collected in the research laboratory or clinic. A repeated 
pain assessment with a maximum recall period of 24 hours for 
pain intensity is consistent with current FDA guidelines for the 
assessment of pain.
Caveats and cautions. Currently, there are no stand-
ardized ambulatory assessment methods for measuring pain 
intensity. There is also limited psychometric data regarding the 
various pain assessment methods that have been developed and 
employed.
Clinical usability. Logistic challenges to collecting data 
outside of the clinic are likely to be primary barriers to using ambu-
latory assessment of pain intensity clinically. This, combined with 
a lack of normative data and clinical cut points, currently limits the 
potential usefulness of this approach for clinical application.
Research usability. Ambulatory assessment of pain has 
been used for decades in the research realm, and its popularity 
has grown tremendously with advances in technology that facil-
itate data collection. The ubiquity of ambulatory assessment of 
pain in research continues to grow, as does the need for develop-
ment and psychometric evaluation of measurement.
CONCLUSIONS
There are many useful measures for the assessment of 
pain in adult patients seen in rheumatologic settings. Using vali-
dated measures that help elucidate key features of the pain expe-
rienced by a patient, including pain severity/intensity, location, and 
quality, are important. Of particular interest and useful to measure, 
is the degree to which pain interferes with functioning. Described 
above are some of the most commonly used measures to address 
those domains. However, no measure is perfect, and most meas-
ures have decided strengths and weaknesses. The BPI is a psy-
chometrically sound measure recommended for use in clinical 
settings to monitor pain severity and its impact on functioning. It is 
easy to administer and score, although there can be costs asso-
ciated with its use. Some aspects of the BPI are rarely reported 
(eg, body map, medications, and pain relief) but could be consid-
ered clinically useful in the care of rheumatology patients. Another 
commonly used measure of pain intensity and interference is the 
DVPRS. The DVPRS was developed for, and has been used in 
primarily in, military and veteran populations. It was created to help 
track changes in pain intensity and interference and is considered 
particularly useful for monitoring within- patient symptom changes 
that commonly occur during transitions between different mili-
tary health care providers. As such, the DVPRS would be most 
useful in military personnel with rheumatic conditions. Also, the 
PROMIS- PI measure is an easy- to- use and psychometrically 
sound measure for the evaluation of pain interference. Although 
this measure does not include an assessment of pain severity like 
the BPI and DVPRS, it is available at no cost and can be adminis-
tered using as few as four items. This measure is available in both 
CAT and static short forms of various lengths, all with strong data 
supportive of its reliability, validity, and responsiveness to change.
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In addition to pain severity and interference, the location of 
pain is crucial to understand. The MBM consists of a manikin with 
35 body areas that can be endorsed to indicate areas of pain. The 
MBM has been used to assess pain in many rheumatic popula-
tions, including osteoarthritis, rheumatoid arthritis, systemic lupus 
erythematosus, fibromyalgia, and low back pain. The body map is 
available in paper or electronic forms at no cost, is easy for patients 
to understand, can be completed in a few minutes, and provides 
information about the location and spread of pain. In addition, the 
number of painful body areas can be summed to provide a score 
that can be used to help assess the degree to which pain is more 
centralized (fibromyalgia- like) (2,22,33). One limitation to this meas-
ure is that the MBM areas of bodily pain are finite, and thus not all 
possible areas of pain are options for patients to endorse.
 As for assessing pain quality, the PD- Q is thought to be use-
ful for the detection of neuropathic pain in patients with chronic 
low back pain, inflammatory arthritis, or osteoarthritis. Other data 
suggest that it is less useful for patients with neck or upper- limb 
conditions. Analysis of the instrument’s psychometric properties 
generally support its use as a brief screening tool. Moreover, it is 
easy for patients to complete, is straightforward to score, and has 
been extensively translated and cross- culturally validated.
Lastly, ambulatory assessment of pain intensity is increas-
ingly ubiquitous in research and holds tremendous potential for 
clinical applications. Detecting fluctuations in pain as they occur 
in real time provides unprecedented opportunities for research-
ers and clinicians to better understand the characteristics and 
underlying mechanisms that influence pain; these insights are 
essential for developing individualized approaches to pain treat-
ment. Coupled with this incredible potential is a current lack of 
scientific evidence supporting a standard approach to ambula-
tory assessment. Establishment of standard methods, population 
norms, and clinical cut points are necessary before ambulatory 
assessment can be truly useful in clinical practice. Still, ambula-
tory assessment of pain can provide useful insights and optimally 
reliable outcome measures in research regardless of the current 
psychometric unknowns.
Although pain assessment in the clinic typically focuses on 
pain itself (ie, intensity, location, and quality), pain perception is 
dependent not only upon nociception but also other mental and 
physical parameters. Thus, there is value in assessing symptom 
clusters associated with pain. These symptom clusters allow clini-
cians to know what other factors are contributing to unwellness/
disability and also can provide additional clinical targets for treat-
ment, given that these symptoms are often correlated with both 
worsening and improvement in pain (94). One such symptom 
cluster that is gaining attention in both adult and pediatric chronic 
pain is remembered by the acronym “SPACE” (sleep, pain, affect, 
cognitive dysfunction, and energy/fatigue) (94,95). SPACE can 
be efficiently assessed using a combination of PROMIS short- 
form measures (eg, sleep- related impairment, pain intensity, anxi-
ety and depression, cognition, and fatigue scales) or by using one 
of the PROMIS profiles such as the PROMIS 29+2 (96), which 
contains scales assessing each of the elements within SPACE. 
This symptom cluster can also be assessed using a combination 
of legacy measures for each symptom, which have been reviewed 
elsewhere (94) (eg, the Pittsburg Sleep Quality Index, the MBM, 
the PD- Q [reviewed above], the HADS, the Multidimensional 
Inventory of Subjective Cognitive Impairment, and the Multidimen-
sional Fatigue Inventory). When such comorbid symptoms are 
identified, addressing these, especially sleep and mood, can have 
an appreciable impact on pain and functioning (97,98).
Pain is complex—no single measure can adequately account 
for the experience and toll of living with chronic pain. The meas-
ures described here and those from past similar publications (1) 
can be used to form the substrate for clinical pain assessment. 
Yet, other symptoms that commonly co- occur with chronic pain 
are also critical to assess (eg, SPACE symptoms). A comprehen-
sive understanding of an individual’s pain experience through the 
use of validated measures can help personalize treatment, with 
the goal of achieving optimum outcomes.
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